Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Potential Breakthrough Therapy for Cancer based on Pepscan’s CLIPS Technology

Pepscan announced that there is an important progress with a drug development program based on its CLIPS technology.

Bicycle Therapeutics team in the UK applied Pepscan’s CLIPS technology to identify a bicyclic CLIPS peptide that selectively binds to a protein (MT1-MMP) present on tumor cells.

A toxin payload has been linked to the high affinity bicyclic peptide to create a ‘Bicycle Drug Conjugate (BDC)’.

The compound, codenamed BT1718, appears to penetrate tumors rapidly. Because of its peptidic nature, BT1718 can be rapidly cleared through the kidney, which minimizes toxicity relating to payload mediated gastrointestinal and liver toxicity.

Superior efficacy of BT1718 has been reported to standard of care controls in multiple preclinical patient and cell-derived mouse xenograft models.

BT1718 will advance to the first stage of clinical testing in human patients; Cancer Research UK, the largest cancer charitable organization in the UK, will sponsor and fund the upcoming Phase 1 study.

CLIPS based lead program is aimed at a new therapy for the treatment of cancer. It confirms the potential of bicyclic '2-CLIPS' peptides as a new generation of biotherapeutics, offering antibody-like affinity and selectivity in a small, fully synthetic molecule.

CLIPS technology is used for the discovery of novel bicyclic 2-CLIPS peptides for therapeutic or diagnostic applications.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024